Mar 22 |
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
|
Mar 22 |
Matinas BioPharma regains compliance with NYSE American
|
Mar 22 |
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
|
Feb 26 |
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
|
Feb 20 |
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
|
Jan 3 |
Matinas BioPharma to Present at Biotech Showcase 2024
|
Dec 27 |
Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
|
Dec 21 |
Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
|
Nov 10 |
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q3 2023 Earnings Call Transcript
|
Nov 9 |
12 Best Day Trading Stocks To Buy
|